Newsroom

MUMBAI, India y JERSEY CITY, Nueva Jersey--(BUSINESS WIRE)--Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (junto con sus filiales y/o empresas vinculadas, “Sun Pharma”) y Organon & Co. (NYSE: OGN) (“Organon”) anunciaron hoy la firma de un acuerdo definitivo en virtud del cual Sun Pharma adquirirá la totalidad de las acciones en circulación de Organon por US$ 14,00 por acción, en una operación íntegramente en efectivo que valúa a Org...

英國劍橋--(BUSINESS WIRE)--(美國商業資訊)-- Mundipharma今日宣布，其全球性ReSPECT臨床試驗取得了積極的III期頂線結果。該試驗旨在評估 REZZAYO® （雷扎芬淨醋酸鹽）用於預防接受異基因造血幹細胞移植（HSCT）的成年患者患侵襲性真菌病（IFD）的效果。 ReSPECT III期臨床試驗是目前規模最大的抗真菌藥物多中心、隨機、雙盲研究之一，旨在評估每週一次的雷扎芬淨與標準抗菌方案（SAR）相比，在接受異基因造血幹細胞移植（HSCT）的成年受試者中，預防由念珠菌、曲霉菌及肺孢子菌引起的侵襲性真菌病（IFD）的效果。接受異基因造血幹細胞移植的患者需長期接受免疫抑制治療，且通常需要進行長時間的抗真菌預防性治療1，因此，差異化給藥方案、更加完善的副作用控制和更低的藥物交互作用風險意義重大，且預期療效相當。 ReSPECT研究達到了美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）設定的主要終點，即第90天的無真菌存活率，結果顯示雷扎芬淨與SAR相比具有非劣效性（分別達60.7%和59.0%）。這表明，雷扎芬淨的差異化藥物動力學/藥效學（PK/PD...

BENGALURU, India--(BUSINESS WIRE)--Embassy Office Parks REIT reported results today for the fourth quarter and full year ended March 31, 2026....

STAMFORD, Conn.--(BUSINESS WIRE)--Enterprises in the U.S. are adopting Salesforce platforms built on unified data architectures and autonomous workflows powered by AI, ISG says....

CLUJ-NAPOCA, Romania--(BUSINESS WIRE)--ZETTA Critical AI, a European innovator in secure, on-premise AI solutions for defense, law enforcement, and intelligence applications, announces the successful deployment of its advanced AI text analytics suite within Veritone’s aiWARE™ platform, leveraging the U.S. Department of Defense’s Iron Bank–certified environment. Addressing the Challenge of Intelligence at Scale Government and law enforcement agencies face increasing pressure to analyze vast amou...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF - October 24.04.2026 FOCT.LN IE0004X8KUG5 100,002.00 USD 2,825,128.31 28.251  ...

TOKYO--(BUSINESS WIRE)--FIDO Inc. (CEO: Kenji Nakamura), a concept branding developer dedicated to creating innovative value in land and living spaces, has officially launched the “THE TIMELESS CONDOMINIUM” project. This initiative seeks to carry forward the intrinsic values rooted in Japan into the world 100 years from now through the form of residences. As its first project, the company unveils details of “THE SILENCE – Furnished by ARMANI/CASA,” a residence set within the historic former Has...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF - July 24.04.2026 FJUL.LN IE000YJBT6I5 100,002.00 USD 2,770,388.28 27.703  ...

WILMINGTON, Delaware--(BUSINESS WIRE)--El M&A transfronterizo se encamina a un fuerte repunte, nueve de cada diez altos responsables de transacciones prevén un aumento de la actividad en los próximos 12 a 24 meses, según una nueva investigación de CSC, proveedor líder de soluciones de administración empresarial y cumplimiento normativo. Sin embargo, pese a este impulso renovado, el riesgo de ejecución está en aumento, ya que el escrutinio regulatorio y los desafíos operativos dificultan con...

CAMBRIDGE, Inglaterra--(BUSINESS WIRE)--A Mundipharma anunciou hoje resultados preliminares positivos da Fase III do ensaio clínico global ReSPECT, que avaliou o REZZAYO® (acetato de rezafungina) para a profilaxia de doenças fúngicas invasivas (IFDs) em pacientes adultos submetidos a transplante alogênico de células-tronco hematopoéticas (HSCT). O ReSPECT, um dos maiores estudos antifúngicos multicêntricos, randomizados e duplo-cegos de Fase III, avaliou a eficácia e a segurança da rezafungina...